

bimatoprost 0.3mg/mL plus timolol 5mg/mL, preservative-free, single-dose eye-drops (Ganfort[®] Unit Dose Preservative Free) (No: 906/13)

Allergan Ltd

06 September 2013

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

bimatoprost plus timolol preservative-free eye-drops (Ganfort[®] Unit Dose Preservative Free) are accepted for restricted use within NHS Scotland.

Indication under review: for the reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

SMC restriction: to use in patients who have proven sensitivity to preservatives.

SMC has previously accepted preserved bimatoprost plus timolol eye-drops for use in NHS Scotland. This preparation is more expensive than the equivalent multi-dose eye drop preparation with preservative.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 12 August 2013.

Chairman, Scottish Medicines Consortium